Tumor Infiltrating Lymphocytes (TILs) Market: Breakthrough Forecast Study Predicts Astounding Growth in the Upcoming Years | Iovance Biotherapeutics (IOV-4001 and LN-144/Lifileucel)

November 30 19:44 2023
Tumor Infiltrating Lymphocytes (TILs) Market: Breakthrough Forecast Study Predicts Astounding Growth in the Upcoming Years | Iovance Biotherapeutics (IOV-4001 and LN-144/Lifileucel)
Delveinsight Business Research LLP
As per DelveInsight, the Tumor Infiltrating Lymphocytes Market is anticipated to evolve immensely in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the launch of emerging therapies during the forecast period of 2023–2032.

DelveInsight’s “Tumor Infiltrating Lymphocytes  Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Tumor Infiltrating Lymphocytes market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Tumor Infiltrating Lymphocyte drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Tumor Infiltrating Lymphocytes treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Tumor Infiltrating Lymphocytes (TILs): An Overview

Lymphocytes, or white blood cells, are an important part of the immune system that helps the body fight off infections or eliminate diseased cells. Lymphocytes, made up of T cells and B cells, are constantly patrolling the body to identify cells that shouldn’t be present, including cancer.

As cancers grow, lymphocytes recognize these cells as abnormal and penetrate the tumor. These are the tumor-infiltrating lymphocytes or TILs. Once in the tumor, the TILs begin working to kill cancer cells. Sometimes, they’re prevented from doing that by brakes in the immune system or signals from the tumor that weakens the immune response. Immune checkpoint inhibitors were developed to block some of those breaks and unleash the immune cells to attack cancer.

The interaction between cancer and immune cells in the tumor microenvironment (TME) is thought to be crucial for the control of the development and progression of malignant tumors. Accordingly, tumor-infiltrating lymphocytes (TILs) have been identified in primary tumor tissue, tumor-bearing lymph nodes, and metastases of numerous cancer types. TILs are defined as lymphocytes within and around cancer cells and have been associated with a survival benefit.

Currently, TIL therapies are only available through clinical trials. For patients who enroll in a TIL clinical trial, the process begins with a tumor biopsy. That biopsy is then taken to a clinical laboratory, such as our Cell Therapy Manufacturing Facility, to isolate the TILs.

Tumor Infiltrating Lymphocytes Market Key Facts

  • According to the American Cancer Society, about 97,610 new melanomas will be diagnosed in the US in 2023. Out of the total number of cases, around 58,120 cases will be diagnosed in men and 39,490 cases in women.

  • In 2022, according to ASCO, an estimated 236,740 adults (117,910 men and 118,830 women) in the United States were diagnosed with lung cancer.

  • According to SEER, it is estimated that there were around 62,210 cases of pancreatic cancer in the US, in 2022. These cases made up about 3.2% of all new cancer cases in the United States

  • According to ASCO, lung cancer was the second most commonly diagnosed cancer. NSCLC is the most common type of lung cancer in the United States, accounting for 82% of all lung cancer diagnoses.

  • As per Cancer Research UK, there are around 12,400 new head and neck cancer cases in the UK every year. Head and neck cancer is the 8th most common cancer in the UK, accounting for 3% of all new cancer cases. Incidence rates for head and neck cancer in the UK are highest in people aged 70 to 74

  • According to the Global Cancer Observatory, the incidence cases of melanoma in France were 16,449 in 2020. These cases are expected to increase in the upcoming years.

Tumor Infiltrating Lymphocytes Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Tumor Infiltrating Lymphocytes pipeline therapies. It also thoroughly assesses the Tumor Infiltrating Lymphocytes market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Tumor Infiltrating Lymphocytes drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Tumor Infiltrating Lymphocytes Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Tumor Infiltrating Lymphocytes epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Tumor Infiltrating Lymphocytes epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Tumor Infiltrating Lymphocytes Epidemiology, Segmented as –

  • Total Cases of Solid Tumors (e.g. Metastatic Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, and others) in the 7MM (2019–2032) 

  • Patients on TIL therapies in the 7MM (2019–2032) 

  • Treatable cases by Line of therapies in the 7MM (2019–2032)

Tumor Infiltrating Lymphocytes Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Tumor Infiltrating Lymphocytes market or expected to be launched during the study period. The analysis covers the Tumor Infiltrating Lymphocytes market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Tumor Infiltrating Lymphocytes drugs based on their sale and market share.

The report also covers the Tumor Infiltrating Lymphocytes pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Tumor Infiltrating Lymphocytes companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Tumor Infiltrating Lymphocytes Market Will Evolve and Grow by 2032 @ 


Tumor Infiltrating Lymphocytes Therapeutics Analysis

Over the past decade, cell-based immunotherapy has become a powerful strategy in solid cancer therapy. Tumor-infiltrating lymphocytes (TILs) are a group of intratumoral lymphocytes. With the development of new technologies, the isolation and generation of TILs from tumor tissues have improved.

Recent clinical studies demonstrated that adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for advanced solid tumors showed good efficacy. TIL therapy is a type of cell-based immunotherapy using the patient’s immune cells from the microenvironment of the solid tumor to kill tumor cells.

Tumor-infiltrating lymphocyte (TIL) therapy has been investigated as a treatment modality for melanoma for almost 20 years. As an autologous cell therapy, manufacturing the infusion product is a highly specialized process involving tumor harvest and the extraction and large-scale ex vivo expansion of TILs.

There are currently no FDA-approved TIL cell therapies. The safety and efficacy of TIL cell therapies are under investigation. Various TIL therapies are being investigated, such as LN-144/LN-145 and IOV-4001. These therapies have shown promising results and are expected to change the market dynamics as far as cancer treatment is concerned.

Tumor Infiltrating Lymphocytes Companies and Emerging Therapies

  • LN-144/Lifileucel: Iovance Biotherapeutics

  • IOV-4001: Iovance Biotherapeutics

And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Tumor Infiltrating Lymphocytes Competitive Intelligence Analysis

4. Tumor Infiltrating Lymphocytes Market Overview at a Glance

5. Tumor Infiltrating Lymphocytes Disease Background and Overview

6. Tumor Infiltrating Lymphocytes Patient Journey

7. Tumor Infiltrating Lymphocytes Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Tumor Infiltrating Lymphocytes Treatment Algorithm, Current Treatment, and Medical Practices

9. Tumor Infiltrating Lymphocytes Unmet Needs

10. Key Endpoints of Tumor Infiltrating Lymphocytes Treatment

11. Tumor Infiltrating Lymphocytes Marketed Therapies

12. Tumor Infiltrating Lymphocytes Emerging Drugs and Latest Therapeutic Advances

13. Tumor Infiltrating Lymphocytes Seven Major Market Analysis

14. Attribute Analysis

15. Tumor Infiltrating Lymphocytes Market Outlook (In US, EU5, and Japan)

16. Tumor Infiltrating Lymphocytes Companies Active in the Market

17. Tumor Infiltrating Lymphocytes Access and Reimbursement Overview

18. KOL Views on the Tumor Infiltrating Lymphocytes Market

19. Tumor Infiltrating Lymphocytes Market Drivers

20. Tumor Infiltrating Lymphocytes Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Uterine Serous Carcinoma Market

“Uterine Serous Carcinoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Uterine Serous Carcinoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Uterine Serous Carcinoma market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research